A Study of Retatrutide (LY3437943) Compared to Tirzepatide (LY3298176) in Adults Who Have Obesity
Launched by ELI LILLY AND COMPANY · Oct 25, 2024
Trial Information
Current as of April 27, 2025
Active, not recruiting
Keywords
ClinConnect Summary
This clinical trial is studying two medications, retatrutide and tirzepatide, to see which one is more effective and safe for adults who have obesity. The trial will last about 89 weeks, and researchers are looking for participants aged 18 and older who have obesity and have previously tried to lose weight through diet without success.
To participate, individuals should not have experienced significant weight changes recently or had any surgical treatments for obesity in the past. They should also not have had any serious heart issues or certain medical conditions related to the thyroid or pancreas. Those who join the study can expect regular check-ins to monitor their health and weight as they take either retatrutide or tirzepatide. This trial aims to help find better treatment options for people living with obesity.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Have obesity and a history of at least one self-reported unsuccessful dietary effort to reduce body weight.
- Exclusion Criteria:
- • Have a self-reported change in body weight \>5 kilograms (kg) (11 pounds) within 90 days before screening.
- • Have a prior or planned surgical treatment for obesity.
- • Have a prior or planned endoscopic procedure and/or device-based therapy for obesity.
- • Have taken weight loss drugs, including over-the-counter medications, within 90 days prior to screening.
- • Have a family or personal history of medullary thyroid carcinoma (MTC) or multiple endocrine neoplasia syndrome type 2 (MEN-2).
- * Have had within the past 90 days before screening:
- • acute myocardial infarction
- • cerebrovascular accident (stroke)
- • coronary revascularization
- • hospitalization for unstable angina, or
- • hospitalization due to congestive heart failure.
- • Have New York Heart Association Functional Classification Class IV congestive heart failure.
- • Have a history of chronic or acute pancreatitis.
About Eli Lilly And Company
Eli Lilly and Company is a global healthcare leader dedicated to creating innovative medicines that improve patient outcomes across a range of therapeutic areas, including diabetes, oncology, immunology, and neurodegenerative diseases. With a rich history of scientific research and a commitment to advancing healthcare, Lilly invests significantly in clinical trials to develop new treatments and enhance existing therapies. The company prioritizes patient safety and ethical standards in its clinical research, fostering collaboration with healthcare professionals and stakeholders to ensure the delivery of high-quality, evidence-based solutions that address unmet medical needs worldwide.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Chicago, Illinois, United States
Bridgeport, Connecticut, United States
Gainesville, Georgia, United States
Valhalla, New York, United States
Walnut Creek, California, United States
Baton Rouge, Louisiana, United States
Charlottesville, Virginia, United States
Bay City, Michigan, United States
New Haven, Connecticut, United States
Honolulu, Hawaii, United States
Spring Valley, California, United States
West Des Moines, Iowa, United States
Miami, Florida, United States
San Diego, California, United States
St. George, Utah, United States
Chattanooga, Tennessee, United States
Saint Peters, Missouri, United States
Saint George, Utah, United States
Monroe, North Carolina, United States
Aurora, Colorado, United States
Oldenburg, Schleswig Holstein, Germany
Sunrise, Florida, United States
Fargo, North Dakota, United States
Essen, Nordrhein Westfalen, Germany
Shavano Park, Texas, United States
Greenville, South Carolina, United States
Essen, Nordrhein Westfalen, Germany
Leipzig, Sachsen, Germany
Hamburg, , Germany
Lublin, Lubelskie, Poland
Houston, Texas, United States
Southfield, Michigan, United States
Henderson, Nevada, United States
Ponce, , Puerto Rico
Wilmington, North Carolina, United States
Ruda Slaska, śląskie, Poland
Poznan, Wielkopolskie, Poland
Białystok, Podlaskie, Poland
Albany, New York, United States
Stonecrest, Georgia, United States
Bialystok, Podlaskie, Poland
Greensboro, North Carolina, United States
New York, New York, United States
Houston, Texas, United States
Ramos Mejía, Buenos Aires, Argentina
Dayton, Ohio, United States
Bialystok, Podlaskie, Poland
Hamburg, , Germany
Lodz, łódzkie, Poland
Poznań, Wielkopolskie, Poland
Buenos Aires, Ciudad Autónoma De Buenos Aires, Argentina
Ciudad Autonoma De Buenos Aires, Ciudad Autónoma De Buenos Aires, Argentina
Villingen Schwenningen, Baden Württemberg, Germany
Tempe, Arizona, United States
Köln, Nordrhein Westfalen, Germany
Lingen, Niedersachsen, Germany
Brownsville, Texas, United States
Lublin, Lubelskie, Poland
Ciudad Autónoma De Buenos Aires, , Argentina
Hollywood, Florida, United States
New York, New York, United States
Newport Beach, California, United States
Miami, Florida, United States
Vero Beach, Florida, United States
Columbus, Georgia, United States
Albany, New York, United States
Ciudad Autonoma De Buenos Aires, Ciudad Autónoma De Buenos Aires, Argentina
Bialystok, Podlaskie, Poland
St. Peters, Missouri, United States
Patients applied
RP
RM
SB
RM
BH
MT
Trial Officials
Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)
Study Director
Eli Lilly and Company
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported